Fluctuation of Anti–Domain 1 and Anti– β 2 ‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies
Arthritis & Rheumatology · 2023-06 · 75 (6) · 984-995
DOI: 10.1002/art.42459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 02.04.2023. Verfasst von Cecilia B Chighizola und 19 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Rheumatology Unit, ASST G. Pini-CTO, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
The present study was undertaken to longitudinally evaluate titers of antibodies against β 2 ‐glycoprotein I (anti‐β 2 GPI) and domain 1 (anti‐D1), to identify predictors of variations in anti‐β 2 GPI and anti‐D1 titers, and to clarify whether antibody titer fluctuations predict thrombosis in a large international cohort of patients who were persistently positive for antiphospholipid antibodies (aPL) in the APS ACTION Registry.
Methods
Patients with available blood samples from at least 4 time points (at baseline [year 1] and at years 2–4 of follow‐up) were included. Detection of anti‐β 2 GPI and anti‐D1 IgG antibodies was performed using chemiluminescence (BIO‐FLASH; INOVA Diagnostics).
Results
Among 230 patients in the study cohort, anti‐D1 and anti‐β 2 GPI titers decreased significantly over time ( P < 0.0001 and P = 0.010, respectively). After adjustment for age, sex, and number of positive aPL tests, we found that the fluctuations in anti‐D1 and anti‐β 2 GPI titer levels were associated with treatment with hydroxychloroquine (HCQ) at each time point. Treatment with HCQ, but not immunosuppressive agents, was associated with 1.3‐fold and 1.4‐fold decreases in anti‐D1 and anti‐β 2 GPI titers, respectively. Incident vascular events were associated with 1.9‐fold and 2.1‐fold increases in anti‐D1 and anti‐β 2 GPI titers, respectively. Anti‐D1 and anti‐β 2 GPI titers at the time of thrombosis were lower compared to titers at other time points. A 1.6‐fold decrease in anti‐D1 titers and a 2‐fold decrease in anti‐β 2 GPI titers conferred odds ratios for incident thrombosis of 6.0 (95% confidence interval [95% CI] 0.62–59.3) and 9.4 (95% CI 1.1–80.2), respectively.
Conclusion
Treatment with HCQ and incident vascular events in aPL‐positive patients predicted significant anti‐D1 and anti‐β 2 GPI titer fluctuations over time. Both anti‐D1 and anti‐β 2 GPI titers decreased around the time of thrombosis, with potential clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Rheumatology Unit, ASST G. Pini-CTO, University of Milan, Milan, Italy.
- Reumatologia, University of Sao Paulo, Sao Paulo, Brazil.
- First Department of Propaedeutic and Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
- Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna, Universidad del País Vasco/Euskal Herriko Unibertsitatea, BioCruces Health Research Institute, Hospital Universitario Cruces, Barakaldo,…
- Hospital for Joint Diseases, New York University, New York.
ORCID-Profile: Cecilia B Chighizola, Maria Tektonidou, Guillermo Ruiz-Irastorza, Paul Fortin, Laura Andreoli, Michelle A Petri, Doruk Erkan
Zitieren
APA
Chighizola, C. B., Pregnolato, F., Andrade, D., Tektonidou, M., Pengo, V., Ruiz-Irastorza, G., Belmont, H. M., Gerosa, M., Fortin, P., Branch, D. W., Andreoli, L., Petri, M. A., Cervera, R., Knight, J. S., Willis, R., Efthymiou, M., Cohen, H., Erkan, D., Bertolaccini, M. L., & Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) (2023). Fluctuation of Anti–Domain 1 and Anti– β 2 ‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies. Arthritis & Rheumatology, 75(6), 984-995. https://doi.org/10.1002/art.42459
Vancouver
Chighizola CB, Pregnolato F, Andrade D, Tektonidou M, Pengo V, Ruiz-Irastorza G, et al. Fluctuation of Anti–Domain 1 and Anti– β 2 ‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies. Arthritis & Rheumatology. 2023;75(6):984-995. doi:10.1002/art.42459
BibTeX
@article{Chighizola2023,
author = {Chighizola, Cecilia B and Pregnolato, Francesca and Andrade, Danieli and Tektonidou, Maria and Pengo, Vittorio and Ruiz-Irastorza, Guillermo and Belmont, H Michael and Gerosa, Maria and Fortin, Paul and Branch, D Ware and Andreoli, Laura and Petri, Michelle A and Cervera, Ricard and Knight, Jason S and Willis, Rohan and Efthymiou, Maria and Cohen, Hannah and Erkan, Doruk and Bertolaccini, Maria Laura and Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION), Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)},
title = {Fluctuation of Anti–Domain 1 and Anti– β 2 ‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies},
journal = {Arthritis & Rheumatology},
year = {2023},
volume = {75},
number = {6},
pages = {984--995},
doi = {10.1002/art.42459}
}
EUVIMED